VEGF-A inhibition ameliorates podocyte apoptosis via repression of activating protein 1 in diabetes

American Journal of Nephrology

Volumn 40, Issue 6, 2014, Pages 523-534

  Bai, Xiaoyan ^a   Geng, Jian ^a   Li, Xiao ^a   Yang, Fang ^a   Tian, Jianwei ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

AP 1; Apoptosis; Diabetes; Podocyte; VEGF A inhibition

Indexed keywords

ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; BEVACIZUMAB; CREATININE; DNA NUCLEOTIDYLEXOTRANSFERASE; GLUCOSE; PROTEIN BCL 2; PROTEIN C FOS; PROTEIN C JUN; SMALL INTERFERING RNA; STREPTOZOCIN; TRANSCRIPTION FACTOR AP 1; VASCULOTROPIN A; ANGIOGENESIS INHIBITOR; ANTHRA(1,9-CD)PYRAZOL-6(2H)-ONE; ANTHRACENE DERIVATIVE; GLUCOSE BLOOD LEVEL; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; FLOW CYTOMETRY; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LUCIFERASE ASSAY; MALE; NICK END LABELING; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROTEIN TARGETING; RAT; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING; ALBUMINURIA; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; CYTOLOGY; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; GENETIC TRANSFECTION; GENETICS; GLUCOSE BLOOD LEVEL; HEK293 CELL LINE; KIDNEY; METABOLISM; SPRAGUE DAWLEY RAT; URINE;

ALBUMINURIA; ANGIOGENESIS INHIBITORS; ANIMALS; ANTHRACENES; ANTIBODIES, MONOCLONAL, HUMANIZED; APOPTOSIS; BLOOD GLUCOSE; CREATININE; DIABETES MELLITUS, EXPERIMENTAL; HEK293 CELLS; HUMANS; KIDNEY; PODOCYTES; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-FOS; PROTO-ONCOGENE PROTEINS C-JUN; RATS, SPRAGUE-DAWLEY; RNA, SMALL INTERFERING; STREPTOZOCIN; TRANSCRIPTION FACTOR AP-1; TRANSFECTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84923554833     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000369942     Document Type: Article

References (32)

1. Bai XY, Basgen JM: Podocyte number in the maturing rat kidney. Am J Nephrol 2011; 33: 91-96.
2. Chen Y, Gui D, Chen J, He D, Luo Y, Wang N: Down-regulation of PERK-ATF4-CHOP pathway by Astragaloside IV is associated with the inhibition of endoplasmic reticulum stressinduced podocyte apoptosis in diabetic rats. Cell Physiol Biochem 2014; 33: 1975-1987.
3. Wang H, Misaki T, Taupin V, Eguchi A, Ghosh P, Farquhar MG: GIV/girdin links vascular endothelial growth factor signaling to Akt survival signaling in podocytes independent of nephrin. J Am Soc Nephrol 2014;pii:ASN. 2013090985, Epub ahead of print.
4. Bai X, Li X, Tian J, Zhou Z: Antiangiogenic treatment diminishes renal injury and dysfunction via regulation of local AKT in early experimental diabetes. PLoS One 2014; 9:e96117.
5. Susztak K, Raff AC, Schiffer M, Bottinger EP: Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes 2006; 55: 225-233.
6. Verzola D, Gandolfo MT, Ferrario F, Rastaldi MP, Villaggio B, Gianiorio F, Giannoni M, Rimoldi L, Lauria F, Miji M, Deferrari G, Garibotto G: Apoptosis in the kidneys of patients with type II diabetic nephropathy. Kidney Int 2007; 72: 1262-1272.
7. DebRoy A, Vogel SM, Soni D, Sundivakkam PC, Malik AB, Tiruppathi C: Endotoxin-induced STIM1 expression in endothelial cells requires cooperative signaling of transcription factors NF-KB and AP1/C-Fos and mediates lung vascular hyper-permeability. J Biol Chem 2014;289:24188-24201.
8. Park SY, Kim KH, Seo KW, Bae JU, Kim YH, Lee SJ, Lee WS, Kim CD: Resistin derived from diabetic perivascular adipose tissue upregulates vascular expression of osteopontin via the AP-1 signalling pathway. J Pathol 2014; 232: 87-97.
9. Tischer E, Mitchell R, Hartman T, Silva M, Gospodarowicz D, Fiddes JC, Abraham JA: The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 1991; 266: 11947-11954.
10. Diaz BV, Lenoir MC, Ladoux A, Frelin C, Demarchez M, Michel S: Regulation of vascular endothelial growth factor expression in human keratinocytes by retinoids. J Biol Chem 2000; 275: 642-650.
11. Feng H, Xiang H, Mao YW, Wang J, Liu JP, Huang XQ, Liu Y, Liu SJ, Luo C, Zhang XJ, Liu Y, Li DW: Human Bcl-2 activates ERK signaling pathway to regulate activating protein-1, lens epithelium-derived growth factor and downstream genes. Oncogene 2004; 23: 7310-7321.
12. Yang KS, Lim JH, Kim TW, Kim MY, Kim Y, Chung S, Shin SJ, Choi BS, Kim HW, Kim YS, Chang YS, Kim HW, Park CW: Vascular endothelial growth factor-receptor 1 inhibition aggravates diabetic nephropathy through eNOS signaling pathway in db/db mice. PLoS One 2014; 9:e94540.
13. Saleem MA, O'Hare MJ, Reiser J, Coward RJ, Inward CD, Farren T, Xing CY, Ni L, Mathieson PW, Mundel P: A conditionally immortalized human podocyte cell line demonstrating nephrin and podocin expression. J Am Soc Nephrol 2002; 13: 630-638.
14. Ahmed S, Vorasubin N, Lopez IA, Hosokawa S, Ishiyama G, Ishiyama A: The expression of glutamate aspartate transporter (GLAST) within the human cochlea and its distribution in various patient populations. Brain Res 2013; 1529: 134-142.
15. Brosius FC, Coward RJ: Podocytes, signaling pathways, and vascular factors in diabetic kidney disease. Adv Chronic Kidney Dis 2014; 21: 304-310.
16. Kim D, Lim S, Park M, Choi J, Kim J, Han H, Yoon K, Kim K, Lim J, Park S: Ubiquitination-dependent CARM1 degradation facilitates Notch1-mediated podocyte apoptosis in diabetic nephropathy. Cell Signal 2014; 26: 1774-1782.
17. Daehn I, Casalena G, Zhang T, Shi S, Fenninger F, Barasch N, Yu L, D'Agati V, Schlondorff D, Kriz W, Haraldsson B, Bottinger EP: Endothelial mitochondrial oxidative stress determines podocyte depletion in segmental glomerulosclerosis. J Clin Invest 2014; 124: 1608-1621.
18. Potla U, Ni J, Vadaparampil J, Yang G, Leventhal JS, Campbell KN, Chuang PY, Morozov A, He JC, D'Agati VD, Klotman PE, Kaufman L: Podocyte-specific RAP1GAP expression contributes to focal segmental glomerulosclerosis-associated glomerular injury. J Clin Invest 2014; 124: 1757-1769.
19. Dong W, Li Y, Gao M, Hu M, Li X, Mai S, Guo N, Yuan S, Song L: IKKalpha contributes to UVB-induced VEGF expression by regulating AP-1 transactivation. Nucleic Acids Res 2012; 40: 2940-2955.
20. Rohr-Udilova N, Sieghart W, Eferl R, Stoiber D, Bjorkhem-Bergman L, Eriksson LC, Stolze K, Hayden H, Keppler B, Sagmeister S, Grasl-Kraupp B, Schulte-Hermann R, Peck-Radosavljevic M: Antagonistic effects of selenium and lipid peroxides on growth control in early hepatocellular carcinoma. Hepatology 2012; 55: 1112-1121.
21. Cook HT, Tarzi R, D'Souza Z, Laurent G, Lin WC, Aitman TJ, Mechta-Grigoriou F, Behmoaras J: AP-1 transcription factor JunD confers protection from accelerated nephrotoxic nephritis and control podocyte-specific VEGFA expression. Am J Pathol 2011; 179: 134-140.
22. Ma J, Matsusaka T, Yang HC, Zhong J, Takagi N, Fogo AB, Kon V, Ichikawa I: Induction of podocyte-derived VEGF ameliorates podocyte injury and subsequent abnormal glomerular development caused by puromycin aminonucleoside. Pediatr Res 2011; 70: 83-89.
23. Sung SH, Ziyadeh FN, Wang A, Pyagay PE, Kanwar YS, Chen S: Blockade of vascular endothelial growth factor signaling ameliorates diabetic albuminuria in mice. J Am Soc Nephrol 2006; 17: 3093-3104.
24. Yamamoto Y, Maeshima Y, Kitayama H, Kitamura S, Takazawa Y, Sugiyama H, Yamasaki Y, Makino H: Tumstatin peptide, an inhibitor of angiogenesis, prevents glomerular hypertrophy in the early stage of diabetic nephropathy. Diabetes 2004; 53: 1831-1840.
25. Schrijvers BF, De Vriese AS, Tilton RG, Van de Voorde J, Denner L, Lameire NH, Flyvbjerg A: Inhibition of vascular endothelial growth factor (VEGF) does not affect early renal changes in a rat model of lean type 2 diabetes. Horm Metab Res 2005; 37: 21-25.
26. Ku CH, White KE, Dei Cas A, Hayward A, Webster Z, Bilous R, Marshall S, Viberti G, Gnudi L: Inducible overexpression of sFlt-1 in podocytes ameliorates glomerulopathy in diabetic mice. Diabetes 2008; 57: 2824-2833.
27. Hohenstein B, Hausknecht B, Boehmer K, Riess R, Brekken RA, Hugo CP: Local VEGF activity but not VEGF expression is tightly regulated during diabetic nephropathy in man. Kidney Int 2006; 69: 1654-1661.
28. Sivaskandarajah GA, Jeansson M, Maezawa Y, Eremina V, Baelde HJ, Quaggin SE: VEGFA protects the glomerular microvasculature in diabetes. Diabetes 2012; 61: 2958-2966.
29. Eremina V, Sood M, Haigh J, Nagy A, Lajoie G, Ferrara N, Gerber HP, Kikkawa Y, Miner JH, Quaggin SE: Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 2003; 111: 707-716.
30. Hara A, Wada T, Furuichi K, Sakai N, Kawachi H, Shimizu F, Shibuya M, Matsushima K, Yokoyama H, Egashira K, Kaneko S: Blockade of VEGF accelerates proteinuria, via decrease in nephrin expression in rat crescentic glomerulonephritis. Kidney Int 2006; 69: 1986-1995.
31. Muller-Deile J, Worthmann K, Saleem M, Tossidou I, Haller H, Schiffer M: The balance of autocrine VEGF-A and VEGF-C determines podocyte survival. Am J Physiol Renal Physiol 2009; 297:F1656-F1667.
32. Bertuccio C, Veron D, Aggarwal PK, Holzman L, Tufro A: Vascular endothelial growth factor receptor 2 direct interaction with nephrin links VEGF-A signals to actin in kidney podocytes. J Biol Chem 2011; 286: 39933-39944.